Literature DB >> 22056545

Discriminative value of inflammatory biomarkers for suspected sepsis.

Ephraim L Tsalik1, L Brett Jaggers, Seth W Glickman, Raymond J Langley, Jennifer C van Velkinburgh, Lawrence P Park, Vance G Fowler, Charles B Cairns, Stephen F Kingsmore, Christopher W Woods.   

Abstract

BACKGROUND: Circulating biomarkers can facilitate sepsis diagnosis, enabling early management and improved outcomes. Procalcitonin (PCT) has been suggested to have superior diagnostic utility compared to other biomarkers. STUDY
OBJECTIVES: To define the discriminative value of PCT, interleukin-6 (IL-6), and C-reactive protein (CRP) for suspected sepsis.
METHODS: PCT, CRP, and IL-6 were correlated with infection likelihood, sepsis severity, and septicemia. Multivariable models were constructed for length-of-stay and discharge to a higher level of care.
RESULTS: Of 336 enrolled subjects, 60% had definite infection, 13% possible infection, and 27% no infection. Of those with infection, 202 presented with sepsis, 28 with severe sepsis, and 17 with septic shock. Overall, 21% of subjects were septicemic. PCT, IL6, and CRP levels were higher in septicemia (median PCT 2.3 vs. 0.2 ng/mL; IL-6 178 vs. 72 pg/mL; CRP 106 vs. 62 mg/dL; p < 0.001). Biomarker concentrations increased with likelihood of infection and sepsis severity. Using receiver operating characteristic analysis, PCT best predicted septicemia (0.78 vs. IL-6 0.70 and CRP 0.67), but CRP better identified clinical infection (0.75 vs. PCT 0.71 and IL-6 0.69). A PCT cutoff of 0.5 ng/mL had 72.6% sensitivity and 69.5% specificity for bacteremia, as well as 40.7% sensitivity and 87.2% specificity for diagnosing infection. A combined clinical-biomarker model revealed that CRP was marginally associated with length of stay (p = 0.015), but no biomarker independently predicted discharge to a higher level of care.
CONCLUSIONS: In adult emergency department patients with suspected sepsis, PCT, IL-6, and CRP highly correlate with several infection parameters, but are inadequately discriminating to be used independently as diagnostic tools.
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22056545      PMCID: PMC3740117          DOI: 10.1016/j.jemermed.2011.05.072

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  41 in total

1.  Contamination of catheter-drawn blood cultures.

Authors:  R J Everts; E N Vinson; P O Adholla; L B Reller
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

2.  Serum procalcitonin in diagnosis of bacteremia.

Authors:  Ubonvan Jongwutiwes; Klairung Suitharak; Surapee Tiengrim; Visanu Thamlikitkul
Journal:  J Med Assoc Thai       Date:  2009-03

3.  Etiology of illness in patients with severe sepsis admitted to the hospital from the emergency department.

Authors:  Alan C Heffner; James M Horton; Michael R Marchick; Alan E Jones
Journal:  Clin Infect Dis       Date:  2010-03-15       Impact factor: 9.079

4.  Disease progression in hemodynamically stable patients presenting to the emergency department with sepsis.

Authors:  Seth W Glickman; Charles B Cairns; Ronny M Otero; Christopher W Woods; Ephraim L Tsalik; Raymond J Langley; Jennifer C van Velkinburgh; Lawrence P Park; Lawrence T Glickman; Vance G Fowler; Stephen F Kingsmore; Emanuel P Rivers
Journal:  Acad Emerg Med       Date:  2010-04       Impact factor: 3.451

5.  Additional value of procalcitonin for diagnosis of infection in patients with fever at the emergency department.

Authors:  Martijn D de Kruif; Maarten Limper; Herman Gerritsen; C Arnold Spek; Dees P M Brandjes; Hugo ten Cate; Patrick M Bossuyt; Pieter H Reitsma; Eric C M van Gorp
Journal:  Crit Care Med       Date:  2010-02       Impact factor: 7.598

6.  A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis.

Authors:  Nathan I Shapiro; Stephen Trzeciak; Judd E Hollander; Robert Birkhahn; Ronny Otero; Tiffany M Osborn; Eugene Moretti; H Bryant Nguyen; Kyle J Gunnerson; David Milzman; David F Gaieski; Munish Goyal; Charles B Cairns; Long Ngo; Emanuel P Rivers
Journal:  Crit Care Med       Date:  2009-01       Impact factor: 7.598

7.  Sepsis redefined: the search for surrogate markers.

Authors:  Ephraim L Tsalik; Christopher W Woods
Journal:  Int J Antimicrob Agents       Date:  2009       Impact factor: 5.283

8.  Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock.

Authors:  Anand Kumar; Paul Ellis; Yaseen Arabi; Dan Roberts; Bruce Light; Joseph E Parrillo; Peter Dodek; Gordon Wood; Aseem Kumar; David Simon; Cheryl Peters; Muhammad Ahsan; Dan Chateau
Journal:  Chest       Date:  2009-08-20       Impact factor: 9.410

9.  Efficacy of procalcitonin in the early diagnosis of bacterial infections in a critical care unit.

Authors:  Akiko Nakamura; Hideo Wada; Makoto Ikejiri; Tsuyoshi Hatada; Hiroyuki Sakurai; Yoshiko Matsushima; Junji Nishioka; Kazuo Maruyama; Shuji Isaji; Taichi Takeda; Tsutomu Nobori
Journal:  Shock       Date:  2009-06       Impact factor: 3.454

10.  Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome.

Authors:  Pierre Emmanuel Charles; Claire Tinel; Saber Barbar; Serge Aho; Sébastien Prin; Jean Marc Doise; Nils Olivier Olsson; Bernard Blettery; Jean Pierre Quenot
Journal:  Crit Care       Date:  2009-03-16       Impact factor: 9.097

View more
  53 in total

1.  Biomarkers in sepsis.

Authors:  Keith R Walley
Journal:  Curr Infect Dis Rep       Date:  2013-10       Impact factor: 3.725

Review 2.  Are there new approaches for diagnosis, therapy guidance and outcome prediction of sepsis?

Authors:  Dubravka Kojic; Benedikt H Siegler; Florian Uhle; Christoph Lichtenstern; Peter P Nawroth; Markus A Weigand; Stefan Hofer; Thorsten Brenner
Journal:  World J Exp Med       Date:  2015-05-20

3.  Frontline Science: Monocytes sequentially rewire metabolism and bioenergetics during an acute inflammatory response.

Authors:  Xuewei Zhu; Allison Meyers; David Long; Brian Ingram; Tiefu Liu; Barbara K Yoza; Vidula Vachharajani; Charles E McCall
Journal:  J Leukoc Biol       Date:  2019-01-11       Impact factor: 4.962

4.  Molecular diagnosis of sepsis: New aspects and recent developments.

Authors:  O Liesenfeld; L Lehman; K-P Hunfeld; G Kost
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2014-03-14

Review 5.  Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock.

Authors:  Brenda Ng Andriolo; Regis B Andriolo; Reinaldo Salomão; Álvaro N Atallah
Journal:  Cochrane Database Syst Rev       Date:  2017-01-18

Review 6.  Early Diagnosis of Sepsis: Is an Integrated Omics Approach the Way Forward?

Authors:  Raymond J Langley; Hector R Wong
Journal:  Mol Diagn Ther       Date:  2017-10       Impact factor: 4.074

7.  Plasma interleukin-6 concentration for the diagnosis of sepsis in critically ill adults.

Authors:  Daniel Molano Franco; Ingrid Arevalo-Rodriguez; Marta Roqué I Figuls; Nadia G Montero Oleas; Xavier Nuvials; Javier Zamora
Journal:  Cochrane Database Syst Rev       Date:  2019-04-30

8.  New approaches to sepsis: molecular diagnostics and biomarkers.

Authors:  Konrad Reinhart; Michael Bauer; Niels C Riedemann; Christiane S Hartog
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

9.  Is serum CRP level a reliable inflammatory marker in pediatric nephrotic syndrome?

Authors:  Eran Shostak; Irit Krause; Amit Dagan; Anat Ben-Dor; Meital Keidar; Miriam Davidovits
Journal:  Pediatr Nephrol       Date:  2016-03-08       Impact factor: 3.714

10.  Diagnostic value of lipopolysaccharide-binding protein and procalcitonin for sepsis diagnosis in forensic pathology.

Authors:  Marc Augsburger; Katia Iglesias; Daniel Bardy; Patrice Mangin; Cristian Palmiere
Journal:  Int J Legal Med       Date:  2012-10-13       Impact factor: 2.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.